Home > Oncology > ASCO 2021 > Lung Cancer > Patritumab deruxtecan (HER3-DXd) in EGFR TKI-resistant NSCLC

Patritumab deruxtecan (HER3-DXd) in EGFR TKI-resistant NSCLC

Presented By
Dr Jänne Pasi, Dana Farber Cancer Institute, MA, USA
Conference
ASCO 2021
Trial
Phase 1
Patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate consisting of a monoclonal antibody to HER3 attached to a topoisomerase I inhibitor, demonstrated anti-tumour activity across various EGFR TKI resistance mechanisms in heavily pretreated, metastatic/locally advanced EGFR-mutated non-small cell lung cancer (NSCLC). EGFR-directed TKIs are the standard of care for patients with EGFR-mutated NSCLC. However, the development of various resistance mechanisms commonly leads to progression. Platinum-based chemotherapy following EGFR TKI failure has limited efficacy. Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate consisting of a fully human monoclonal antibody to HER3 – expressed in 83% of NSCLC tumours – attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker [1]. Dr Jänne Pasi (Dana Farber Cancer Institute, MA, USA) presented efficacy and safety ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on